Click for best price
Pulmonary Arterial Hypertension PAH Drugs Market Size, Share 2024
This research report provides a comprehensive analysis of the Pulmonary Arterial Hypertension (PAH) Drugs market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Pulmonary Arterial Hypertension (PAH) Drugs market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Pulmonary Arterial Hypertension (PAH) Drugs, challenges faced by the industry, and potential opportunities for market players.
The global Pulmonary Arterial Hypertension (PAH) Drugs market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Pulmonary Arterial Hypertension (PAH) Drugs market presents opportunities for various stakeholders, including Hospitals, Clinics. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Pulmonary Arterial Hypertension (PAH) Drugs market. Additionally, the growing consumer demand present avenues for market expansion.
The global Pulmonary Arterial Hypertension (PAH) Drugs market was valued at US$ million in 2023 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The research report on the Pulmonary Arterial Hypertension (PAH) Drugs market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Pulmonary Arterial Hypertension (PAH) Drugs market.
Market Overview: The report provides a comprehensive overview of the Pulmonary Arterial Hypertension (PAH) Drugs market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Inhalation, Injectables), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Pulmonary Arterial Hypertension (PAH) Drugs market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Pulmonary Arterial Hypertension (PAH) Drugs market's trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Pulmonary Arterial Hypertension (PAH) Drugs market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Pulmonary Arterial Hypertension (PAH) Drugs market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Pulmonary Arterial Hypertension (PAH) Drugs market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Pulmonary Arterial Hypertension (PAH) Drugs market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Pulmonary Arterial Hypertension (PAH) Drugs, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Pulmonary Arterial Hypertension (PAH) Drugs market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Pulmonary Arterial Hypertension (PAH) Drugs market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Inhalation
Injectables
Oral Administration
Market segment by Application
Hospitals
Clinics
Other
Global Pulmonary Arterial Hypertension (PAH) Drugs Market Segment Percentages, By Region and Country, 2023 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Pfizer
Glaxosmithkline
Novartis
United Therapeutics
AstraZeneca
Merck
Bayer Healthcare
Actelion Pharmaceuticals
Daiichi Sankyo
Northern Therapeutics
Aires Pharmaceuticals
Arena Pharmaceuticals
Berlin Cures
Eiger BioPharmaceuticals
Reata Pharmaceuticals
Outline of Major Chapters:
Chapter 1: Introduces the definition of Pulmonary Arterial Hypertension (PAH) Drugs, market overview.
Chapter 2: Global Pulmonary Arterial Hypertension (PAH) Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Pulmonary Arterial Hypertension (PAH) Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Pulmonary Arterial Hypertension (PAH) Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Pulmonary Arterial Hypertension (PAH) Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Pulmonary Arterial Hypertension (PAH) Drugs Market, Global Outlook and Forecast 2024-2030 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2023 |
| Forecast Year |
2031 |
| Number of Pages |
139 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Pulmonary Arterial Hypertension (PAH) Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Pulmonary Arterial Hypertension (PAH) Drugs Overall Market Size
2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size: 2023 VS 2030
2.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue, Prospects & Forecasts: 2019-2030
2.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales: 2019-2030
3 Company Landscape
3.1 Top Pulmonary Arterial Hypertension (PAH) Drugs Players in Global Market
3.2 Top Global Pulmonary Arterial Hypertension (PAH) Drugs Companies Ranked by Revenue
3.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Companies
3.4 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Companies
3.5 Global Pulmonary Arterial Hypertension (PAH) Drugs Price by Manufacturer (2019-2024)
3.6 Top 3 and Top 5 Pulmonary Arterial Hypertension (PAH) Drugs Companies in Global Market, by Revenue in 2023
3.7 Global Manufacturers Pulmonary Arterial Hypertension (PAH) Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Pulmonary Arterial Hypertension (PAH) Drugs Players in Global Market
3.8.1 List of Global Tier 1 Pulmonary Arterial Hypertension (PAH) Drugs Companies
3.8.2 List of Global Tier 2 and Tier 3 Pulmonary Arterial Hypertension (PAH) Drugs Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size Markets, 2023 & 2030
4.1.2 Inhalation
4.1.3 Injectables
4.1.4 Oral Administration
4.2 By Type - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue & Forecasts
4.2.1 By Type - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue, 2019-2024
4.2.2 By Type - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue, 2025-2030
4.2.3 By Type - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share, 2019-2030
4.3 By Type - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales & Forecasts
4.3.1 By Type - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales, 2019-2024
4.3.2 By Type - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales, 2025-2030
4.3.3 By Type - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share, 2019-2030
4.4 By Type - Global Pulmonary Arterial Hypertension (PAH) Drugs Price (Manufacturers Selling Prices), 2019-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2023 & 2030
5.1.2 Hospitals
5.1.3 Clinics
5.1.4 Other
5.2 By Application - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue & Forecasts
5.2.1 By Application - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue, 2019-2024
5.2.2 By Application - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue, 2025-2030
5.2.3 By Application - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share, 2019-2030
5.3 By Application - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales & Forecasts
5.3.1 By Application - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales, 2019-2024
5.3.2 By Application - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales, 2025-2030
5.3.3 By Application - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share, 2019-2030
5.4 By Application - Global Pulmonary Arterial Hypertension (PAH) Drugs Price (Manufacturers Selling Prices), 2019-2030
6 Sights by Region
6.1 By Region - Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2023 & 2030
6.2 By Region - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue & Forecasts
6.2.1 By Region - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue, 2019-2024
6.2.2 By Region - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue, 2025-2030
6.2.3 By Region - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share, 2019-2030
6.3 By Region - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales & Forecasts
6.3.1 By Region - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales, 2019-2024
6.3.2 By Region - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales, 2025-2030
6.3.3 By Region - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share, 2019-2030
6.4 North America
6.4.1 By Country - North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue, 2019-2030
6.4.2 By Country - North America Pulmonary Arterial Hypertension (PAH) Drugs Sales, 2019-2030
6.4.3 US Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2019-2030
6.4.4 Canada Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2019-2030
6.4.5 Mexico Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2019-2030
6.5 Europe
6.5.1 By Country - Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue, 2019-2030
6.5.2 By Country - Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales, 2019-2030
6.5.3 Germany Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2019-2030
6.5.4 France Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2019-2030
6.5.5 U.K. Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2019-2030
6.5.6 Italy Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2019-2030
6.5.7 Russia Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2019-2030
6.5.8 Nordic Countries Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2019-2030
6.5.9 Benelux Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2019-2030
6.6 Asia
6.6.1 By Region - Asia Pulmonary Arterial Hypertension (PAH) Drugs Revenue, 2019-2030
6.6.2 By Region - Asia Pulmonary Arterial Hypertension (PAH) Drugs Sales, 2019-2030
6.6.3 China Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2019-2030
6.6.4 Japan Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2019-2030
6.6.5 South Korea Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2019-2030
6.6.6 Southeast Asia Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2019-2030
6.6.7 India Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2019-2030
6.7 South America
6.7.1 By Country - South America Pulmonary Arterial Hypertension (PAH) Drugs Revenue, 2019-2030
6.7.2 By Country - South America Pulmonary Arterial Hypertension (PAH) Drugs Sales, 2019-2030
6.7.3 Brazil Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2019-2030
6.7.4 Argentina Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2019-2030
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue, 2019-2030
6.8.2 By Country - Middle East & Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales, 2019-2030
6.8.3 Turkey Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2019-2030
6.8.4 Israel Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2019-2030
6.8.5 Saudi Arabia Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2019-2030
6.8.6 UAE Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2019-2030
7 Manufacturers & Brands Profiles
7.1 Pfizer
7.1.1 Pfizer Company Summary
7.1.2 Pfizer Business Overview
7.1.3 Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Major Product Offerings
7.1.4 Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in Global (2019-2024)
7.1.5 Pfizer Key News & Latest Developments
7.2 Glaxosmithkline
7.2.1 Glaxosmithkline Company Summary
7.2.2 Glaxosmithkline Business Overview
7.2.3 Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Major Product Offerings
7.2.4 Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in Global (2019-2024)
7.2.5 Glaxosmithkline Key News & Latest Developments
7.3 Novartis
7.3.1 Novartis Company Summary
7.3.2 Novartis Business Overview
7.3.3 Novartis Pulmonary Arterial Hypertension (PAH) Drugs Major Product Offerings
7.3.4 Novartis Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in Global (2019-2024)
7.3.5 Novartis Key News & Latest Developments
7.4 United Therapeutics
7.4.1 United Therapeutics Company Summary
7.4.2 United Therapeutics Business Overview
7.4.3 United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Major Product Offerings
7.4.4 United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in Global (2019-2024)
7.4.5 United Therapeutics Key News & Latest Developments
7.5 AstraZeneca
7.5.1 AstraZeneca Company Summary
7.5.2 AstraZeneca Business Overview
7.5.3 AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Major Product Offerings
7.5.4 AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in Global (2019-2024)
7.5.5 AstraZeneca Key News & Latest Developments
7.6 Merck
7.6.1 Merck Company Summary
7.6.2 Merck Business Overview
7.6.3 Merck Pulmonary Arterial Hypertension (PAH) Drugs Major Product Offerings
7.6.4 Merck Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in Global (2019-2024)
7.6.5 Merck Key News & Latest Developments
7.7 Bayer Healthcare
7.7.1 Bayer Healthcare Company Summary
7.7.2 Bayer Healthcare Business Overview
7.7.3 Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Major Product Offerings
7.7.4 Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in Global (2019-2024)
7.7.5 Bayer Healthcare Key News & Latest Developments
7.8 Actelion Pharmaceuticals
7.8.1 Actelion Pharmaceuticals Company Summary
7.8.2 Actelion Pharmaceuticals Business Overview
7.8.3 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Major Product Offerings
7.8.4 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in Global (2019-2024)
7.8.5 Actelion Pharmaceuticals Key News & Latest Developments
7.9 Daiichi Sankyo
7.9.1 Daiichi Sankyo Company Summary
7.9.2 Daiichi Sankyo Business Overview
7.9.3 Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Major Product Offerings
7.9.4 Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in Global (2019-2024)
7.9.5 Daiichi Sankyo Key News & Latest Developments
7.10 Northern Therapeutics
7.10.1 Northern Therapeutics Company Summary
7.10.2 Northern Therapeutics Business Overview
7.10.3 Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Major Product Offerings
7.10.4 Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in Global (2019-2024)
7.10.5 Northern Therapeutics Key News & Latest Developments
7.11 Aires Pharmaceuticals
7.11.1 Aires Pharmaceuticals Company Summary
7.11.2 Aires Pharmaceuticals Business Overview
7.11.3 Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Major Product Offerings
7.11.4 Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in Global (2019-2024)
7.11.5 Aires Pharmaceuticals Key News & Latest Developments
7.12 Arena Pharmaceuticals
7.12.1 Arena Pharmaceuticals Company Summary
7.12.2 Arena Pharmaceuticals Business Overview
7.12.3 Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Major Product Offerings
7.12.4 Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in Global (2019-2024)
7.12.5 Arena Pharmaceuticals Key News & Latest Developments
7.13 Berlin Cures
7.13.1 Berlin Cures Company Summary
7.13.2 Berlin Cures Business Overview
7.13.3 Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Major Product Offerings
7.13.4 Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in Global (2019-2024)
7.13.5 Berlin Cures Key News & Latest Developments
7.14 Eiger BioPharmaceuticals
7.14.1 Eiger BioPharmaceuticals Company Summary
7.14.2 Eiger BioPharmaceuticals Business Overview
7.14.3 Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Major Product Offerings
7.14.4 Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in Global (2019-2024)
7.14.5 Eiger BioPharmaceuticals Key News & Latest Developments
7.15 Reata Pharmaceuticals
7.15.1 Reata Pharmaceuticals Company Summary
7.15.2 Reata Pharmaceuticals Business Overview
7.15.3 Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Major Product Offerings
7.15.4 Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in Global (2019-2024)
7.15.5 Reata Pharmaceuticals Key News & Latest Developments
8 Global Pulmonary Arterial Hypertension (PAH) Drugs Production Capacity, Analysis
8.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Production Capacity, 2019-2030
8.2 Pulmonary Arterial Hypertension (PAH) Drugs Production Capacity of Key Manufacturers in Global Market
8.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Pulmonary Arterial Hypertension (PAH) Drugs Supply Chain Analysis
10.1 Pulmonary Arterial Hypertension (PAH) Drugs Industry Value Chain
10.2 Pulmonary Arterial Hypertension (PAH) Drugs Upstream Market
10.3 Pulmonary Arterial Hypertension (PAH) Drugs Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Pulmonary Arterial Hypertension (PAH) Drugs Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Key Players of Pulmonary Arterial Hypertension (PAH) Drugs in Global Market
Table 2. Top Pulmonary Arterial Hypertension (PAH) Drugs Players in Global Market, Ranking by Revenue (2023)
Table 3. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Companies, (US$, Mn), 2019-2024
Table 4. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Companies, 2019-2024
Table 5. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Companies, (K Pcs), 2019-2024
Table 6. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Companies, 2019-2024
Table 7. Key Manufacturers Pulmonary Arterial Hypertension (PAH) Drugs Price (2019-2024) & (USD/Pcs)
Table 8. Global Manufacturers Pulmonary Arterial Hypertension (PAH) Drugs Product Type
Table 9. List of Global Tier 1 Pulmonary Arterial Hypertension (PAH) Drugs Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Pulmonary Arterial Hypertension (PAH) Drugs Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 11. By Type ? Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2023 & 2030
Table 12. By Type - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue (US$, Mn), 2019-2024
Table 13. By Type - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue (US$, Mn), 2025-2030
Table 14. By Type - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), 2019-2024
Table 15. By Type - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), 2025-2030
Table 16. By Application ? Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2023 & 2030
Table 17. By Application - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue (US$, Mn), 2019-2024
Table 18. By Application - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue (US$, Mn), 2025-2030
Table 19. By Application - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), 2019-2024
Table 20. By Application - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), 2025-2030
Table 21. By Region ? Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2023 VS 2030
Table 22. By Region - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue (US$, Mn), 2019-2024
Table 23. By Region - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue (US$, Mn), 2025-2030
Table 24. By Region - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), 2019-2024
Table 25. By Region - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), 2025-2030
Table 26. By Country - North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2019-2024
Table 27. By Country - North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2025-2030
Table 28. By Country - North America Pulmonary Arterial Hypertension (PAH) Drugs Sales, (K Pcs), 2019-2024
Table 29. By Country - North America Pulmonary Arterial Hypertension (PAH) Drugs Sales, (K Pcs), 2025-2030
Table 30. By Country - Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2019-2024
Table 31. By Country - Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2025-2030
Table 32. By Country - Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales, (K Pcs), 2019-2024
Table 33. By Country - Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales, (K Pcs), 2025-2030
Table 34. By Region - Asia Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2019-2024
Table 35. By Region - Asia Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2025-2030
Table 36. By Region - Asia Pulmonary Arterial Hypertension (PAH) Drugs Sales, (K Pcs), 2019-2024
Table 37. By Region - Asia Pulmonary Arterial Hypertension (PAH) Drugs Sales, (K Pcs), 2025-2030
Table 38. By Country - South America Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2019-2024
Table 39. By Country - South America Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2025-2030
Table 40. By Country - South America Pulmonary Arterial Hypertension (PAH) Drugs Sales, (K Pcs), 2019-2024
Table 41. By Country - South America Pulmonary Arterial Hypertension (PAH) Drugs Sales, (K Pcs), 2025-2030
Table 42. By Country - Middle East & Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2019-2024
Table 43. By Country - Middle East & Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2025-2030
Table 44. By Country - Middle East & Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales, (K Pcs), 2019-2024
Table 45. By Country - Middle East & Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales, (K Pcs), 2025-2030
Table 46. Pfizer Company Summary
Table 47. Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Product Offerings
Table 48. Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 49. Pfizer Key News & Latest Developments
Table 50. Glaxosmithkline Company Summary
Table 51. Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Product Offerings
Table 52. Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 53. Glaxosmithkline Key News & Latest Developments
Table 54. Novartis Company Summary
Table 55. Novartis Pulmonary Arterial Hypertension (PAH) Drugs Product Offerings
Table 56. Novartis Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 57. Novartis Key News & Latest Developments
Table 58. United Therapeutics Company Summary
Table 59. United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Product Offerings
Table 60. United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 61. United Therapeutics Key News & Latest Developments
Table 62. AstraZeneca Company Summary
Table 63. AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Product Offerings
Table 64. AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 65. AstraZeneca Key News & Latest Developments
Table 66. Merck Company Summary
Table 67. Merck Pulmonary Arterial Hypertension (PAH) Drugs Product Offerings
Table 68. Merck Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 69. Merck Key News & Latest Developments
Table 70. Bayer Healthcare Company Summary
Table 71. Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Product Offerings
Table 72. Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 73. Bayer Healthcare Key News & Latest Developments
Table 74. Actelion Pharmaceuticals Company Summary
Table 75. Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Offerings
Table 76. Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 77. Actelion Pharmaceuticals Key News & Latest Developments
Table 78. Daiichi Sankyo Company Summary
Table 79. Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Product Offerings
Table 80. Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 81. Daiichi Sankyo Key News & Latest Developments
Table 82. Northern Therapeutics Company Summary
Table 83. Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Product Offerings
Table 84. Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 85. Northern Therapeutics Key News & Latest Developments
Table 86. Aires Pharmaceuticals Company Summary
Table 87. Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Offerings
Table 88. Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 89. Aires Pharmaceuticals Key News & Latest Developments
Table 90. Arena Pharmaceuticals Company Summary
Table 91. Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Offerings
Table 92. Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 93. Arena Pharmaceuticals Key News & Latest Developments
Table 94. Berlin Cures Company Summary
Table 95. Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Product Offerings
Table 96. Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 97. Berlin Cures Key News & Latest Developments
Table 98. Eiger BioPharmaceuticals Company Summary
Table 99. Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Offerings
Table 100. Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 101. Eiger BioPharmaceuticals Key News & Latest Developments
Table 102. Reata Pharmaceuticals Company Summary
Table 103. Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Offerings
Table 104. Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 105. Reata Pharmaceuticals Key News & Latest Developments
Table 106. Pulmonary Arterial Hypertension (PAH) Drugs Production Capacity (K Pcs) of Key Manufacturers in Global Market, 2022-2024 (K Pcs)
Table 107. Global Pulmonary Arterial Hypertension (PAH) Drugs Capacity Market Share of Key Manufacturers, 2022-2024
Table 108. Global Pulmonary Arterial Hypertension (PAH) Drugs Production by Region, 2019-2024 (K Pcs)
Table 109. Global Pulmonary Arterial Hypertension (PAH) Drugs Production by Region, 2025-2030 (K Pcs)
Table 110. Pulmonary Arterial Hypertension (PAH) Drugs Market Opportunities & Trends in Global Market
Table 111. Pulmonary Arterial Hypertension (PAH) Drugs Market Drivers in Global Market
Table 112. Pulmonary Arterial Hypertension (PAH) Drugs Market Restraints in Global Market
Table 113. Pulmonary Arterial Hypertension (PAH) Drugs Raw Materials
Table 114. Pulmonary Arterial Hypertension (PAH) Drugs Raw Materials Suppliers in Global Market
Table 115. Typical Pulmonary Arterial Hypertension (PAH) Drugs Downstream
Table 116. Pulmonary Arterial Hypertension (PAH) Drugs Downstream Clients in Global Market
Table 117. Pulmonary Arterial Hypertension (PAH) Drugs Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Pulmonary Arterial Hypertension (PAH) Drugs Segment by Type in 2023
Figure 2. Pulmonary Arterial Hypertension (PAH) Drugs Segment by Application in 2023
Figure 3. Global Pulmonary Arterial Hypertension (PAH) Drugs Market Overview: 2023
Figure 4. Key Caveats
Figure 5. Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size: 2023 VS 2030 (US$, Mn)
Figure 6. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue, 2019-2030 (US$, Mn)
Figure 7. Pulmonary Arterial Hypertension (PAH) Drugs Sales in Global Market: 2019-2030 (K Pcs)
Figure 8. The Top 3 and 5 Players Market Share by Pulmonary Arterial Hypertension (PAH) Drugs Revenue in 2023
Figure 9. By Type - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2023 & 2030
Figure 10. By Type - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share, 2019-2030
Figure 11. By Type - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share, 2019-2030
Figure 12. By Type - Global Pulmonary Arterial Hypertension (PAH) Drugs Price (USD/Pcs), 2019-2030
Figure 13. By Application - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2023 & 2030
Figure 14. By Application - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share, 2019-2030
Figure 15. By Application - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share, 2019-2030
Figure 16. By Application - Global Pulmonary Arterial Hypertension (PAH) Drugs Price (USD/Pcs), 2019-2030
Figure 17. By Region - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2023 & 2030
Figure 18. By Region - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share, 2019 VS 2023 VS 2030
Figure 19. By Region - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share, 2019-2030
Figure 20. By Region - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share, 2019-2030
Figure 21. By Country - North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share, 2019-2030
Figure 22. By Country - North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share, 2019-2030
Figure 23. US Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2019-2030
Figure 24. Canada Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2019-2030
Figure 25. Mexico Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2019-2030
Figure 26. By Country - Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share, 2019-2030
Figure 27. By Country - Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share, 2019-2030
Figure 28. Germany Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2019-2030
Figure 29. France Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2019-2030
Figure 30. U.K. Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2019-2030
Figure 31. Italy Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2019-2030
Figure 32. Russia Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2019-2030
Figure 33. Nordic Countries Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2019-2030
Figure 34. Benelux Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2019-2030
Figure 35. By Region - Asia Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share, 2019-2030
Figure 36. By Region - Asia Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share, 2019-2030
Figure 37. China Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2019-2030
Figure 38. Japan Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2019-2030
Figure 39. South Korea Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2019-2030
Figure 40. Southeast Asia Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2019-2030
Figure 41. India Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2019-2030
Figure 42. By Country - South America Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share, 2019-2030
Figure 43. By Country - South America Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share, 2019-2030
Figure 44. Brazil Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2019-2030
Figure 45. Argentina Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2019-2030
Figure 46. By Country - Middle East & Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share, 2019-2030
Figure 47. By Country - Middle East & Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share, 2019-2030
Figure 48. Turkey Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2019-2030
Figure 49. Israel Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2019-2030
Figure 50. Saudi Arabia Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2019-2030
Figure 51. UAE Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2019-2030
Figure 52. Global Pulmonary Arterial Hypertension (PAH) Drugs Production Capacity (K Pcs), 2019-2030
Figure 53. The Percentage of Production Pulmonary Arterial Hypertension (PAH) Drugs by Region, 2023 VS 2030
Figure 54. Pulmonary Arterial Hypertension (PAH) Drugs Industry Value Chain
Figure 55. Marketing Channels
